Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells

Citation
Y. Ishii et al., Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells, LEUK RES, 25(9), 2001, pp. 813-820
Citations number
31
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
LEUKEMIA RESEARCH
ISSN journal
01452126 → ACNP
Volume
25
Issue
9
Year of publication
2001
Pages
813 - 820
Database
ISI
SICI code
0145-2126(200109)25:9<813:PIISAP>2.0.ZU;2-P
Abstract
Various inhibitors of protein kinases regulate the growth and differentiati on of human leukemic cell lines. The pyridinyl imidazole inhibitor SB203580 has been widely used to elucidate the role of p38 kinase in a wide array o f biological systems, In the present investigation, we found that SB203580 effectively induced the granulocytic differentiation of human promyelocytic HL-60 cells. In addition to morphological differentiation, it also induced NBT-reduction, lysozyme activity and growth-inhibition. It also induced th e differentiation of human myeloid leukemia HT93 and ML-1 cells, but not of other cell lines, such as NB4, U937, THP-1, K562 and HEL. This differentia tion was not associated with the inhibition of p38 kinase activity, but was closely associated with the activation of extracellular signal- regulated kinase. These results demonstrate a new activity for this drug. (C) 2001 El sevier Science Ltd. All rights reserved.